Ustekinumab
Brand name: Stelara
Rank #19 of 500 drugs by total cost
$852.3M
Total Cost
31,974
Total Claims
$852.3M
Total Cost
1,173
Prescribers
$27K
Cost per Claim
1,700
Beneficiaries
48,761
30-Day Fills
$727K
Avg Cost/Provider
27
Avg Claims/Provider
About Ustekinumab
Ustekinumab (sold as Stelara) was prescribed 31,974 times by 1,173 Medicare Part D providers in 2023, costing the program $852.3M. At $27K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 16 | Mirabegron (Myrbetriq) | $927.5M | 1,407,073 |
| 17 | Tirzepatide (Mounjaro) | $877.9M | 680,457 |
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
| 19 | Ustekinumab (Stelara) | $852.3M | 31,974 |
| 20 | Paliperidone Palmitate (Invega Sustenna) | $832.3M | 252,388 |
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology